Status:
COMPLETED
Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies
Lead Sponsor:
Barwon Health
Collaborating Sponsors:
University of Melbourne
National Health and Medical Research Council, Australia
Conditions:
Graves' Ophthalmopathy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether radioactive iodine, as compared to anti-thyroid medications, is a risk factor for the development or progression of thyroid-associated ophthalmopathy ...
Eligibility Criteria
Inclusion
- Graves' disease diagnosed in the last 3 months, regardless of the presence of ophthalmopathy
Exclusion
- Pre-existing eye disease: e.g. orbital surgery, orbital irradiation or significant loss of vision
- Age \< 18 years
- Inability to consent to participation in the study
- Pregnancy
- History of radio-active iodine therapy
Key Trial Info
Start Date :
August 1 2003
Trial Type :
INTERVENTIONAL
End Date :
January 1 2006
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00430547
Start Date
August 1 2003
End Date
January 1 2006
Last Update
February 2 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Barwon Health - The Geelong Hospital
Geelong, Victoria, Australia, 3220